Alto Neuroscience (ANRO) — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Claim profile

ANRO · Stock Price

USD 24.07+21.85 (+984.23%)

Market Cap: $836.7M

Historical price data

Market Cap: $836.7MPipeline: 11 drugsPatents: 3Founded: 2019Employees: 51-200HQ: Los Altos, United States

Sector Ranking#20 in AI / Machine Learning #65 in Diagnostics & Precision Medicine

Overview

Alto Neuroscience is a precision psychiatry company leveraging a proprietary AI-driven biomarker platform to develop targeted therapies for major depressive disorder, bipolar depression, and schizophrenia. Founded in 2019 and built on 15 years of foundational neurobiology research, the company has rapidly advanced a multi-asset clinical pipeline. Its core strategy is to use objective measures of brain function to identify patient subpopulations most likely to respond to its novel drug candidates, thereby increasing clinical success rates and commercial potential.

PsychiatryNeuroscience

Technology Platform

A proprietary AI-driven Precision Psychiatry Platform that integrates multi-modal brain biomarkers (EEG, cognitive tests, wearables) to identify patient subpopulations most likely to respond to specific neuropsychiatric drug candidates.

Pipeline

11

11 drugs in pipeline

Drug	Indication	Stage
Duloxetine + Bupropion	Major Depressive Disorder	Approved
Sertraline + Escitalopram	Major Depressive Disorder	Approved
ALTO-100 PO tablet	Major Depressive Disorder	Phase 2
ALTO-100 + Placebo	Major Depressive Disorder	Phase 2
ALTO-100 + Placebo	Bipolar Disorder I or II With a Major Depressive Episode	Phase 2

Funding History

7

Total raised:$384M

Series E$45MAlpha Wave VenturesJul 9, 2024

Series D$45MAlpha Wave VenturesMay 16, 2024

Series C$45MAlpha Wave VenturesMar 25, 2024

IPO$129MUndisclosedFeb 2, 2024

Opportunities

The massive, inefficient neuropsychiatric drug market presents a multi-billion dollar opportunity for a precision approach.

Successfully pairing drugs with predictive biomarkers can lead to higher clinical success rates, premium pricing, and dominant market share in defined patient segments, while addressing a profound unmet patient need.

Risk Factors

High clinical development risk where trial failures could invalidate the core platform.

Regulatory and reimbursement challenges for novel drug-biomarker combinations.

Significant financial volatility and dependence on capital markets for funding in the pre-revenue stage.

Competitive Landscape

Faces competition from large pharma with commercial scale, other CNS-focused biotechs (e.g., Neumora), and broad AI drug discovery platforms. Alto's key differentiator is its fully integrated, closed-loop platform specializing in psychiatry, combining proprietary biomarker discovery with targeted drug development.